We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
TEPEZZA (Amgen Australia Pty Ltd)
Product name
TEPEZZA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
151 (255 working days)
Active ingredients
teprotumumab
Registration type
NCE/NBE
Indication
TEPEZZA is indicated for the treatment of moderate to severe Thyroid Eye Disease (TED) (see section 5.1 Pharmacodynamic properties – Clinical trials).
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available